Taysha Gene Therapies annual stock-based compensation
2020
2021
2022
2023
2024
2025
Taysha Gene Therapies Stock-Based Compensation Growth & History (TSHA)
Taysha Gene Therapies's stock-based compensation was $13.3M for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.3M | $195,000 | +1.49% |
| 2024 | 2024-12-31 | $13.1M | $5.2M | +65.76% |
| 2023 | 2023-12-31 | $7.9M | −$10.1M | −56.19% |
| 2022 | 2022-12-31 | $18.0M | −$141,000 | −0.78% |
| 2021 | 2021-12-31 | $18.2M | $14.8M | +442.16% |
| 2020 | 2020-12-31 | $3.4M | — | — |
Taysha Gene Therapies quarterly stock-based compensation
Q4.19
Q1.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.8M | $2.6M | +82.13% |
| Q1 2026 | 2026-03-31 | $5.5M | $2.3M | +68.40% |
| Q4 2025 | 2025-12-31 | $3.5M | $313,000 | +9.73% |
| Q3 2025 | 2025-09-30 | $3.3M | −$72,000 | −2.14% |
| Q2 2025 | 2025-06-30 | $3.2M | −$142,000 | −4.26% |
| Q1 2025 | 2025-03-31 | $3.3M | $96,000 | +3.00% |
| Q4 2024 | 2024-12-31 | $3.2M | $1.2M | +63.41% |
| Q3 2024 | 2024-09-30 | $3.4M | $1.3M | +64.56% |
| Q2 2024 | 2024-06-30 | $3.3M | $1.1M | +49.95% |
| Q1 2024 | 2024-03-31 | $3.2M | $1.5M | +90.93% |
| Q4 2023 | 2023-12-31 | $2.0M | −$2.1M | −52.04% |
| Q3 2023 | 2023-09-30 | $2.0M | −$2.4M | −54.36% |
| Q2 2023 | 2023-06-30 | $2.2M | −$1.9M | −46.34% |
| Q1 2023 | 2023-03-31 | $1.7M | −$3.7M | −68.57% |
| Q4 2022 | 2022-12-31 | $4.1M | −$852,000 | −17.19% |
| Q3 2022 | 2022-09-30 | $4.5M | −$616,000 | −12.11% |
| Q2 2022 | 2022-06-30 | $4.1M | −$408,000 | −8.97% |
| Q1 2022 | 2022-03-31 | $5.3M | $1.7M | +48.27% |
| Q4 2021 | 2021-12-31 | $5.0M | — | — |
| Q3 2021 | 2021-09-30 | $5.1M | $3.7M | +279.27% |
| Q2 2021 | 2021-06-30 | $4.5M | — | — |
| Q1 2021 | 2021-03-31 | $3.6M | $3.6M | — |
| Q3 2020 | 2020-09-30 | $1.3M | — | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
| Q4 2019 | 2019-12-31 | $0 | — | — |
Taysha Gene Therapies stock-based compensation trends
Over the last five fiscal years, Taysha Gene Therapies's stock-based compensation increased from $3.4M to $13.3M, a change of $9.9M. The latest reported quarter, Q2 2026, shows $5.8M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗